Myricx Bio
Developing the first class of ADCs based on NMT inhibition
- Headquarters
- London
- Employees
- 1–10
- Founded
- 2019
- Business Model
- B2B
- Website
- myricx.bio
- Total Funding
- $113.0M
- Last Round
- $113.0M Venture RoundJul 2024
About
Myricx Bio is a UK biotech company focused on discovering and developing a novel class of payloads for antibody drug conjugates (ADCs) based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer. Founded on world-leading NMT biology and chemistry research, Myricx is advancing a pipeline of NMTi-ADC programs against validated oncology targets including B7-H3 and HER2 toward clinical development.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account